Antibiotics in the clinical pipeline in October 2019 - The Journal of Antibiotics

-



mac avium :: Article Creator

Side Effects Of Arikayce: What You Need To Know

ALLERGIC REACTION

For some people, Arikayce can cause an allergic reaction. Symptoms of allergic reaction can be mild to serious.

Mild allergic reaction symptoms may include:

Symptoms of a serious allergic reaction may include:

Inflammation in the lungs from an allergic reaction to Arikayce was a rare side effect that happened in the drug's studies.

Symptoms of lung inflammation may include:

What might help

If you have mild symptoms of an allergic reaction, such as a mild rash, call your doctor right away. They may suggest a treatment to manage your symptoms and can determine whether you should continue Arikayce treatment.

If you have symptoms of a severe allergic reaction, such as swelling or difficulty breathing, call 911 or your local emergency number right away. These symptoms could be life threatening and require immediate medical care.

If your doctor confirms you've had a serious allergic reaction to Arikayce, they may have you switch to a different treatment.


Insmed's Strategic Growth And Market Potential Drive Buy Recommendation

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on INSM stock, giving a Buy rating on November 8.

Joseph Schwartz's rating is based on Insmed's strategic management decisions and promising market potential. The company recently closed their $500 million ATM equity offering, which indicates a strong focus on maximizing shareholder value. Management believes that the remaining ATM capacity was relatively insignificant compared to the company's size and growth opportunities, suggesting a prudent financial strategy.Furthermore, Insmed's promising ASPEN data positions them to potentially access the lucrative non-cystic fibrosis bronchiectasis market, valued at over $5 billion at peak. Schwartz acknowledges the company's consistent execution in clinical, regulatory, and commercial areas, which contributes to a positive outlook. While the closure of the ATM has fueled acquisition speculations, the company's strategic alignment with investor interests and robust cash position supports the Buy rating.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Insmed (INSM) Company Description:

Insmed, Inc. Is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.


Insmed's Options: A Look At What The Big Money Is Thinking

Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed INSM revealed 13 unusual trades.

Delving into the details, we found 7% of traders were bullish, while 76% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $855,036, and 3 were calls, valued at $419,310.

Expected Price Movements

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $62.5 to $85.0 for Insmed over the recent three months.

Analyzing Volume & Open Interest

In today's trading context, the average open interest for options of Insmed stands at 2968.25, with a total volume reaching 15,604.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Insmed, situated within the strike price corridor from $62.5 to $85.0, throughout the last 30 days.

Insmed Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume INSM CALL TRADE BULLISH 01/17/25 $1.2 $0.75 $1.2 $85.00 $360.0K 7.1K 3.0K INSM PUT SWEEP BEARISH 01/17/25 $4.1 $3.8 $4.06 $62.50 $150.3K 504 2.3K INSM PUT SWEEP BEARISH 01/17/25 $4.5 $3.4 $3.9 $62.50 $142.3K 504 365 INSM PUT SWEEP BEARISH 01/17/25 $4.0 $3.7 $4.0 $62.50 $138.4K 504 1.5K INSM PUT SWEEP BEARISH 01/17/25 $4.0 $3.7 $4.0 $62.50 $123.2K 504 746 About Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

After a thorough review of the options trading surrounding Insmed, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Where Is Insmed Standing Right Now?
  • With a trading volume of 891,951, the price of INSM is down by -0.03%, reaching $66.27.
  • Current RSI values indicate that the stock is may be approaching oversold.
  • Next earnings report is scheduled for 94 days from now.
    • Professional Analyst Ratings for Insmed

    2 market experts have recently issued ratings for this stock, with a consensus target price of $97.5.

    Unusual Options Activity Detected: Smart Money on the Move

    Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $105. * Reflecting concerns, an analyst from HC Wainwright & Co. Lowers its rating to Buy with a new price target of $90.

    Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Insmed options trades with real-time alerts from Benzinga Pro.

    Market News and Data brought to you by Benzinga APIs

    © 2024 Benzinga.Com. Benzinga does not provide investment advice. All rights reserved.





    Comments

    Post a Comment

    Popular posts from this blog

    Manual on meat inspection for developing countries

    -
    Image
    sinusitis treatment :: Article Creator My 'sinus Infection' Turned Out To Be A One In A Million Nasal Cancer At Just 28 - And Doctors Had To Cut My Eye Out To Save Me By Emily Joshu Health Reporter For Dailymail.Com Published: 06:33 EDT, 20 April 2024Updated: 06:35 EDT, 20 April 2024 A 28 year-old California woman has described the shock of being diagnosed with a deadly sinus cancer that affects fewer than one in a million people - and led to the removal of her right eye. The 'golf ball-sized tumor', which had spread throughout her face, was first mistaken for a sinus infection by the woman's doctors.  Annika, who posts about her condition on TikTok, woke up one morning in 2023 and noticed that the inner corner of her right eye was sore.  While she at first thought nothing of it, by the time the evening rolled around, 'my face started to really, really hurt on the right side,' she said in a video.  The next day, her...
    Read more

    Rash behind ear: Causes, other symptoms, and treatment - Medical News Today

    -
    Image
    A rash behind the ear may occur due to a variety of different medical conditions. Certain viral infections and autoimmune diseases may cause a rash behind the ear in both children and adults. While some causes, such as contact dermatitis, are not concerning, other causes, including rubella, may be more serious. In this article, we look at some of the causes of a rash behind the ear, as well as the other symptoms that they may produce and how to treat them. Contact dermatitis is an allergic reaction to a particular substance. If an allergy-inducing substance comes into contact with the skin behind the ear, a rash can form. Allergens that may cause contact dermatitis behind the ears include: shampoos soaps other hair care products For example, hair dye products contain an ingredient called paraphenylenediamine (PPD), which is a common contact allergen. Symptoms Contact dermatitis causes itchiness, dryness, and flaking of the skin that came into contact with the allergen. Diagnosis A doc...
    Read more

    Freddie Mercury's haunting last picture before tragic death from Aids - Irish Mirror

    -
    Freddie Mercury's final days in 1991 remain enshrined in mystery, nearly 30 years on. The Queen frontman succumbed to his battle with Aids on November 24, having released a public statement just 24 hours previously that confirmed he was HIV+. Rumours had been swirling about his health status for a number of years, with speculation that he had been tested for HIV and Aids as far back as 1986, after his health declined so rapidly that Queen had to halt their 1987 Magic Tour before it was due to finish. Freddie, real name Farrokh Bulsara, had been something of a recluse in his last two years, preferring to stay at his lavish Garden Lodge home in west London's Kensington than rub shoulders with other celebrities at showbiz parties. Tragically, Freddie's health continued to deteriorate in private, as feverish speculation mounted that he was gravely sick. The last known photos of him show how much weight he had lost during his rare public appearances towards the end. On Sep...
    Read more